Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer

RegulatoryapprovedOpamtistomigPositive

AI Analysis

Summary

Leads Biolabs (9887.HK) announced that the FDA granted Fast Track Designation to opamtistomig, a PD-L1/4-1BB bispecific antibody, for first-line advanced or metastatic biliary tract cancer.

Outcome Details

FDA granted Fast Track Designation to opamtistomig (PD-L1/4-1BB bispecific antibody) for first-line advanced or metastatic biliary tract cancer

Importance:6/10

Sentiment:

0.60

Fast TrackFDAbispecific antibodyPD-L14-1BBbiliary tract canceroncology

Related Companies

$CPHI $TRAX

Read the original article

Published by Drugs.com Clinical Trial Results on October 12, 2026 2:10 AM

Read Original